A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2018
At a glance
- Drugs Linagliptin (Primary) ; Glimepiride
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CAROLINA
- Sponsors Boehringer Ingelheim Pharmaceuticals; Unilfarma
- 10 Jun 2017 Biomarkers information updated
- 21 Jun 2016 Planned number of patients changed from 6000 to 6115.
- 21 Jun 2016 Planned End Date changed from 1 Sep 2018 to 1 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History